Quercetin nanoparticles alter pharmacokinetics of bromocriptine, reflecting its enhanced inhibitory action on liver and intestinal CYP 3A enzymes in rats

References

• Andres S, Tejido ML, Bodas R, et al. (2013). Quercetin dietary supplementation of fattening lambs at 0.2% rate reduces discolouration and microbial growth in meat during refrigerated storage. Meat Sci 93:207–12.
   PubMed Web of Science ®Google Scholar
• Ball SE, Maurer G, Zollinger M, et al. (1992). Characterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206-291 in humans. Drug Metab Dispos 20:56–63.
   PubMed Web of Science ®Google Scholar
• Bezirtzoglou EEV. (2012). Intestinal cytochromes P450 regulating the intestinal microbiota and its probiotic profile. Microb Ecol Health Dis 23:1–10.
   Google Scholar
• Boots AW, Wilms LC, Swennen EL, et al. (2008). In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition 24:703–10.
   PubMed Web of Science ®Google Scholar
• Brazier NC, Levine MA. (2003). Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 10:163–9.
   PubMedGoogle Scholar
• Cao X, Gibbs ST, Fang L, et al. (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675–86.
   PubMed Web of Science ®Google Scholar
• Choi JS, Piao YJ, Kang KW. (2011). Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 34:607–13.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Seo MK, Kim IC, Lee YH. (1997). High-performance liquid chromatographic assay of bromocriptine in plasma and eye tissue of the rabbit. J Chromatogr B 694:415–20.
   PubMed Web of Science ®Google Scholar
• Cotreau MM, von Moltke LL, Beinfeld MC, Greenblatt DJ. (2000). Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level. J Pharmacol Toxicol Methods 43:41–54.
   PubMed Web of Science ®Google Scholar
• de Waziers I, Cugnenc PH, Yang CS, et al. (1990). Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387–94.
   PubMed Web of Science ®Google Scholar
• Dian L, Yu E, Chen X, et al. (2014). Enhancing oral bioavailability of quercetin using novel soluplus polymeric micelles. Nanoscale Res Lett 9:684–91.
   Web of Science ®Google Scholar
• Dupuy J, Larrieu G, Sutra JF, et al. (2003). Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet Parasitol 112:337–47.
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Kim DH. (1990). In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11:2275–9.
   PubMed Web of Science ®Google Scholar
• Kalra S, Kalra B, Agrawal N, Kumar S. (2011). Dopamine: the forgotten felon in type 2 diabetes. Recent Pat Endocr Metab Immune Drug Discov 5:61–5.
   PubMedGoogle Scholar
• Kaminsky LS, Fasco MJ. (1991). Small intestinal cytochromes P450. Crit Rev Toxicol 21:407–22.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 59:631–44.
   PubMed Web of Science ®Google Scholar
• Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. (1992). Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Investig 90:1871–8.
   PubMed Web of Science ®Google Scholar
• Kupferschmidt HH, Fattinger KE, Ha HR, et al. (1998). Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 45:355–9.
   PubMed Web of Science ®Google Scholar
• Kvernmo T, Härtter S, Burger E. (2006). A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28:1065–78.
   PubMed Web of Science ®Google Scholar
• Lavellea EC, Sharif S, Thomas NW, et al. (1995). The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Adv Drug Deliv Rev 18:5–22.
   Web of Science ®Google Scholar
• Lei X, Chao H, Zhang Z, et al. (2015). Neuroprotective effects of quercetin in a mouse model of brain ischemic/reperfusion injury via anti-apoptotic mechanisms based on the Akt pathway. Mol Med Rep 12:3688–96.
   PubMed Web of Science ®Google Scholar
• Li H, Zhao X, Ma Y, et al. (2009). Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133:238–44.
   PubMed Web of Science ®Google Scholar
• Lown KS, Bailey DG, Fontana RJ, et al. (1997). Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Investig 99:2545–53.
   PubMed Web of Science ®Google Scholar
• Maurer G, Schreier E, Delaborde S, et al. (1983). Fate and disposition of bromocriptine in animals and man 11: absorption, elimination and metabolism. Eur J Drug Metab Pharmacokin 8:51–62.
   PubMed Web of Science ®Google Scholar
• Md S, Haque S, Fazil M, et al. (2014). Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. Expert Opin Drug Deliv 11:827–42.
   PubMed Web of Science ®Google Scholar
• Miniscalco A, Lundahl J, Regårdh CG, et al. (1992). Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther 261:1195–9.
   PubMed Web of Science ®Google Scholar
• Muller RH, Akkar A. (2004). Drug nanocrystals of poorly soluble drugs. In: Nalwa HS, ed. Encyclopedia of nanoscience and nanotechnology. California: American Scientific Publishers, 627–38.
   Google Scholar
• Nash T. (1953). The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem J 55:416–21.
   PubMed Web of Science ®Google Scholar
• Neerati P, Bedada SK. (2015). Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats. Pharmacol Rep 67:339–44.
   PubMed Web of Science ®Google Scholar
• Nelson MV, Berchou RC, Kareti D, LeWitt PA. (1990). Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin Pharmacol Ther 47:694–7.
   PubMed Web of Science ®Google Scholar
• Paine MF, Shen DD, Kunze KL, et al. (1996). First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14–24.
   PubMed Web of Science ®Google Scholar
• Palle S, Neerati P. (2017). Enhancement of oral bioavailability of rivastigmine with quercetin nanoparticles by inhibiting CYP3A4 and esterases. Pharmacol Rep 69:365–70.
   PubMed Web of Science ®Google Scholar
• Peters WHM, Kremers PG. (1989). Cytochromes P-450 in the intestinal mucosa of man. Biochem Pharmacol 38:1535–8.
   PubMed Web of Science ®Google Scholar
• Peyronneau MA, Delaforge M, Riviere R, et al. (1994). High affinity of ergopeptides for cytochromes p450 3A. Importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine. Eur J Biochem 223:947–56.
   PubMedGoogle Scholar
• Ralph AD. (2011). Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 34:789–94.
   PubMed Web of Science ®Google Scholar
• Rodeiro I, Donato MT, Lahoz A, et al. (2008). Interactions of polyphenols with the P450 system: possible implications on human therapeutics. Mini Rev Med Chem 8:97–106.
   PubMed Web of Science ®Google Scholar
• Ruan LP, Chen S, Yu BY, et al. (2006). Prediction of human absorption of natural compounds by the non-everted rat intestinal sac model. Eur J Med Chem 41:605–10.
   PubMed Web of Science ®Google Scholar
• Schenkman JB, Cinti DL. (1978). Preparation of microsomes with calcium. Methods Enzymol 52:83–9.
   PubMedGoogle Scholar
• Schran HF, Tse FLS, Bhuta SI. (1985). Pharmacokinetics and pharmacodynamics of bromocriptine in the rat. Biopharm Drug Dispos 6:301–11.
   PubMed Web of Science ®Google Scholar
• Shantha KL, Harding DRK. (2000). Preparation and in vitro evaluation of poly (Nvinyl - 2-pyrrolidone-polyethylene glycol diacrylate)-chitosan interpolymeric pH responsive hydrogels for oral drug delivery. Int J Pharm 207:65–70.
   PubMed Web of Science ®Google Scholar
• Shin SC, Choi JS, Li X. (2006). Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm 313:144–9.
   PubMed Web of Science ®Google Scholar
• Sinha R, Srivastava S, Joshi A, et al. (2014). In-vitro anti-proliferative and anti-oxidant activity of galangin, fisetin and quercetin: role of localization and intermolecular interaction in model membrane. Eur J Med Chem 79:102–19.
   PubMed Web of Science ®Google Scholar
• Smith AJ, Kavuru P, Wojtas L, et al. (2011). Cocrystals of quercetin with improved solubility and oral bioavailability. Mol Pharm 8:1867–76.
   PubMed Web of Science ®Google Scholar
• Sudhir NU, Pankaj VD, Vijendra K, et al. (2008). Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition. Biochem Pharmacol 75:1670–6.
   PubMed Web of Science ®Google Scholar
• Takemoto K, Yamazaki H, Tanaka Y, et al. (2003). Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes. Xenobiotica 33:43–55.
   PubMed Web of Science ®Google Scholar
• Van Zanden JJ, Wortelboer HM, Bijlsma S, et al. (2005). Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol 69:699–708.
   PubMed Web of Science ®Google Scholar
• Vessal M, Hemmati M, Vasei M. (2003). Antidiabetic effects of quercetin in streptozocin-induced diabetic rats. Comp Biochem Physiol C Toxicol Pharmacol 135:357–64.
   PubMed Web of Science ®Google Scholar
• Viney L, Dharmpal S, Deepti P. (2016). Proniosomal gel-mediated transdermal delivery of bromocriptine: in vitro and ex vivo evaluation. J Exp Nanosci 11:1044–57.
   Web of Science ®Google Scholar
• Wada S, Kano T, Mita S, et al. (2013). The role of inter-segmental differences in P-glycoprotein expression and activity along the rat small intestine in causing the double-peak phenomenon of substrate plasma concentration. Drug Metab Pharmacokinet 28:98–103.
   PubMed Web of Science ®Google Scholar
• Watkins PB. (1997). The barrier functions of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Del Rev 27:161–70.
   PubMed Web of Science ®Google Scholar
• Weber A, Jäger R, Börner A, et al. (1996). Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 53:41–7.
   PubMed Web of Science ®Google Scholar
• Wu W, Li R, Li X, et al. (2015). Quercetin as an antiviral agent inhibits influenza A virus (IAV) entry. Viruses 8:1–18.
   Web of Science ®Google Scholar
• Zhou S, Gao Y, Jiang W, et al. (2003). Interactions of herbs with cytochrome P450. Drug Metab Rev 35:35–98.
   PubMed Web of Science ®Google Scholar